Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Abbvie inc.    crawled time : 14:12    save search
RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
Published: 2020-12-10 (Crawled : 14:12) - prnewswire.com
ABBV | News | $169.22 0.79% 370K twitter stocktwits trandingview |
Health Technology
 | | O: 0.36% H: 0.01% C: -1.44%
dermatitis phase 3 atopic dermatitis dupixent
Gainers vs Losers
89% 11%

Top 10 Gainers
MTTR | News M | $4.65 167.24% 9.8M twitter stocktwits trandingview |

AGBA | $2.46 96.8% 28M twitter stocktwits trandingview |
Finance
EDBL | News | $6.94 84.57% 1.4M twitter stocktwits trandingview |

CZOO | $7.74 55.11% 2.7M twitter stocktwits trandingview |

VNRX | $0.84 40.0% 2.6M twitter stocktwits trandingview |
Health Technology
ZAPP | $6.02 35.59% 95K twitter stocktwits trandingview |
n/a
OPRT | News | $3.01 33.78% 6.8M twitter stocktwits trandingview |
Finance
MLEC | $1.81 29.29% 2M twitter stocktwits trandingview |
n/a
MTC | $2.0 28.21% 1.7M twitter stocktwits trandingview |
Technology Services
PEGY | $0.0586 27.95% 130M twitter stocktwits trandingview |
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.